Make Informed Investment Decisions with Affordable Access to Experts
Examining the market size for Hemophilia B gene therapy treatments with a focus on uniQure & SparkTicker(s): QURE, ONCE, PFE
Name: Dr Christopher Walsh - MD
Institution: Mount Sinai
- Associate Professor & Director of the Hemophilia Program in the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, Regional Director of ATHN funded Hemophilia Treatment Centers in New England.
- Currently manages 120 patients with Hemophilia B.
- Research focuses on gene therapy of blood diseases. Pioneered the research into Adeno-Associated Virus (AAV) and its first use as a gene therapy vector; early work culminated in the first clinical trial in for gene therapy of patients with Fanconi Anemia Group C and Group A.
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.